Navigation Links
Study Shows Intradigm's RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models
Date:4/14/2008

Findings Support Gene-Silencing Mechanism and Demonstrate Significant Tumor

Growth Inhibition Across Multiple Tumor Models in Mice

PALO ALTO, Calif., April 14 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced study results that demonstrated the company's RNAi Nanoplex (NPX) delivery technology platform is capable of effectively delivering small interfering RNAs (siRNAs) targeting both vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) pathways, two clinically validated pathways in the treatment of various cancers. Study data demonstrated that mice treated with Intradigm's proprietary peptide-based, biodegradable polymer (PolyTran(TM)) carrying each of VEGF-, VEGFR2- or EGFR-targeted siRNAs experienced significant tumor growth inhibition that was similar to that of mice receiving the study's positive control (VEGF antibody Bevacizumab or EGFR tyrosine kinase inhibitor Erlotinib). In addition, mice in the active siRNA treatment groups demonstrated no apparent toxicity or significant weight loss.

These study findings, which also confirmed the gene-silencing mechanism of action of Intradigm's technology, were presented by Intradigm scientists on Sunday, April 13 at the 2008 American Association for Cancer Research (AACR) Annual Meeting in San Diego.

"We are very pleased with these study results as they confirm the gene-silencing mechanism of our RNAi NPX delivery technology, as well as its ability to systemically deliver siRNAs to tumors in a safe and effective manner," said Mohammad Azab, M.D., president and chief executive officer of Intradigm. "Furthermore, by effectively targeting VEGF, VEGFR2, and EGFR, three established oncology targets, with our siRNAs, we have demonstrated the versatility of the RNAi NPX delivery technology which could be translated into multiple product opportunities for Intradigm's pipeline of RNAi
'/>"/>

SOURCE Intradigm Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
2. Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids
3. Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
4. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
5. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
6. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
7. UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting
8. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
9. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
10. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
11. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)... SAN DIEGO, Oct. 7 /- Prometheus Lab..., today announced findings from its,development of...blood test,for irritable bowel syndrome (IBS). The...pression of particular biomarkers in blood samples...ion of these biomarkers,combined with a proprieta...
(Date:10/7/2008)... Results of FLEXX Trial Presented at the Osteoart... Congress, PARSIPPANY, N.J., Oct. 7 /PRNewswire/ ... results from the FLEXX Trial of Osteoarthritis of...luronate), a highly pure,non-avian high molecular ...-HA), is superior to intra-articular saline (IA-sa...
(Date:10/7/2008)... In a clinical study of adults, VYVANSE taken onc...D within one week, PHILADELPHIA, Oct. 7 /PRNewswi...Y), the global specialty biopharmaceutical company...ptember issue of the Journal of,Clinical Psychiatr...Attention Deficit Hyperactivity Disorder (ADHD) sy...
(Date:10/7/2008)... BERKELEY, Calif., Oct. 7 /- Aerovan...fety data from a Phase I trial of its Aerovant,inh...with no evidence of,local irritancy following asth...This 10 mg dose will be the highest of three doses...g study, which is scheduled to begin early,next ye...
Breaking Medicine Technology:Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2EuroDYNA takes lid off the genome 3629 1EuroDYNA takes lid off the genome 3629 2EuroDYNA takes lid off the genome 3629 3EuroDYNA takes lid off the genome 3629 41 in 10 adults has a non earlobe piercing 21798 11 in 10 adults has a non earlobe piercing 21798 2New insight into RA patient priorities and motivators for clinical trial involvement 21796 1New insight into RA patient priorities and motivators for clinical trial involvement 21796 2New insight into RA patient priorities and motivators for clinical trial involvement 21796 3New STAY ON TRACK for Better Prostate Health Program Launches Fathers Day Weekend at NASCAR Race 21794 1New STAY ON TRACK for Better Prostate Health Program Launches Fathers Day Weekend at NASCAR Race 21794 2New STAY ON TRACK for Better Prostate Health Program Launches Fathers Day Weekend at NASCAR Race 21794 3New STAY ON TRACK for Better Prostate Health Program Launches Fathers Day Weekend at NASCAR Race 21794 4
...ALEM--(BUSINESS WIRE)--Mar 7, 2007 - BioLineRx Ltd...ompany, reported,today pre-clinical data from tria...ive in preventing deterioration of the myocardium,...ng left ventricle,dilatation and eventual heart fa... Director of the Neufeld Cardiac Research,Institut...
...t-Ever Placebo-controlled Study in Inoperable Chro...y Endpoint of,Reduction in Pulmonary Vascular Resi...ificant Effect on Dyspnoea Score and,Biological Di..., 2007 -Actelion Ltd (SWX:,ATLN) announced today t...controlled, multicenter study BENEFiT (Bosentan Ef...
Other Medicine Technology:BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 2BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 3Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 2Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 3Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 4Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 5Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 6
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...an to reduce illegal trading and as a clean up dri...couver. Vancouver’s mayor is considering providing...town Eastside before the 2010 Winter Olympics. Ac...an anonymous donor of $500,000 to fund an innovati...
...ing, a Chinese by origin and a hunter by professio...facial transplant.// As of now the doctors say tha...peration could be revealed after sixty days. It is...ors reported to the press that Mr. Li has crossed ...
...s a viral infection and spreads by air borne trans...ber of mumps cases. // Statistics show that more t...ses), Nebraska (139), Kansas (205), Illinois (110)...a (unknown) and Okalahoma (unknown). About sixty-s...
...hampion and grandmaster Vishwanathan Anand will no...e Indian chapter of the Bill and Melinda Gates Fou... the awareness about the HIV/AIDS epidemic in Ind...aigns. He is already well known and respected amon...
Other Medicine News:Health News:Mumps Fever Spreads Unabated In US 2Health News:Chess Champion Anand to Champion HIV/AIDS for Avahan 2
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer
...al growth system, combines orbital shaking, oxygen...r bacterial growth. It is designed for easy integr...Extractor. The uniquely engineered HT-MegaGrowTM h...akers. Plate-holding cassettes allow for high plat...
Inquire
Inquire
Medicine Products: